Journal article
Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole
Abstract
BACKGROUND: MA17 showed improved outcomes in postmenopausal women given extended letrozole (LET) after completing 5 years of adjuvant tamoxifen.
PATIENTS AND METHODS: Exploratory subgroup analyses of disease-free survival (DFS), distant DFS (DDFS), overall survival (OS), toxic effects and quality of life (QOL) in MA17 were performed based on menopausal status at breast cancer diagnosis.
Authors
Goss PE; Ingle JN; Martino S; Robert NJ; Muss HB; Livingston RB; Davidson NE; Perez EA; Chavarri-Guerra Y; Cameron DA
Journal
Annals of Oncology, Vol. 24, No. 2, pp. 355–361
Publisher
Elsevier
Publication Date
February 2013
DOI
10.1093/annonc/mds330
ISSN
0923-7534